Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
MMSE score showed a positive correlation with the Aβ 1-42 concentrations ( r = 0.485; p r = -0.418; p = 0.002).
Why it matters
In 52 patients with early Alzheimer's disease, this pilot cross-sectional study found correlations among CSF markers such as IL-6, NfL, TDP-43, GFAP and GDF-15, with GDF-15's link to MMSE mainly mediated by Aβ 1-42. It is a small pilot biomarker study and does not test any treatment, cure or prevention.
-
Emerging research found air pollution may be associated with incident Alzheimer’s disease (AD) and other dementias.
Why it matters
Across 149 countries from 1990 to 2019, higher fine particulate matter (PM2.5) was associated with a higher burden of Alzheimer's disease and other dementias. This is a global ecological analysis of associations and does not test whether reducing air pollution prevents dementia.
-
The global age-standardized prevalence of AD and other dementias increased from 672 (95% uncertainty interval: 589 to 764) per 100,000 population in 1990 to 694 (603 to 794) per 100,000 population in 2021, with AAPCs of 0.09% (95% confidence interval: 0.06% to 0.11%).
Why it matters
Global age-standardized prevalence of Alzheimer's and other dementias rose slightly from 1990 to 2021, while age-standardized mortality did not change and DALYs increased slightly. High fasting plasma glucose ranked as the highest risk factor for DALYs, suggesting its control may be needed to reduce the dementia burden.
-
A total of 13,659 articles were obtained in this study.
Why it matters
A bibliometric analysis of 13,659 MRI articles in Alzheimer's disease from 2004 to 2023 found exponential growth in publications and identified machine learning and deep learning as recent keyword hotspots. This describes research trends, not a treatment, cure, or prevention.
-
The rising incidence of Alzheimer's disease (AD) poses significant challenges to traditional diagnostic methods, which primarily rely on neuropsychological assessments and brain MRIs.
Why it matters
This study used retinal vessel segmentation from eye imaging to screen for Alzheimer's disease with a classification accuracy of 79%. The authors describe it as a potential economical, non-invasive screening tool, but it is a preliminary framework and does not test treatment or prevention.
-
47/100
The identification of neuroinflammation as a critical factor in Alzheimer's disease (AD) has expanded the focus of research beyond amyloid-β and tau pathology.
Why it matters
This review discusses neuroinflammatory fluid biomarkers GFAP, sTREM2 and YKL-40 for early detection and monitoring of Alzheimer's disease progression. It notes conflicting results for sTREM2 and does not report a treatment or cure.
-
This study was undertaken to compare the performance of plasma p-tau181 with that of [ 18 F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the identification of early biological Alzheimer disease (AD).
Why it matters
A blood test for phosphorylated tau181 identified early Alzheimer's disease better than a brain scan measuring glucose metabolism in 533 people with cognitive impairment. This concerns diagnosis, not treatment or prevention.
-
47/100
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder with a global impact, yet its pathogenesis remains poorly understood.
Why it matters
Using multi-omics data from 87 patients, this study identified plasma proteins, metabolites, and a gut microbe linked to Alzheimer's severity and built AI models to predict it. It concerns prediction and possible drug targets, not a proven treatment or cure.
-
Our findings suggest AD-type tau is not higher in LLD compared to non-depressed, cognitively unimpaired older adults and appears unlikely to contribute to lower gray matter volume in LLD, further underscoring the need to distinguish major depressive disorder from depressive symptoms occurring in early AD.
Why it matters
In this cross-sectional study of 102 adults over age 60, people with late life depression had lower grey matter volume in some regions but similar tau accumulation and amyloid positivity to non-depressed cognitively unimpaired people. This suggests late life depression is not associated with Alzheimer-type tau, but it does not test any treatment, cure or prevention.
-
There were 534 patients who underwent AD CSF biomarkers (Roche Elecsys Aβ42, p-Tau181, total-Tau) from April 1, 2020, through April 23, 2021.
Why it matters
This study evaluated how Alzheimer's spinal fluid biomarkers performed in a tertiary neurology clinic with many non-Alzheimer's cases, including normal pressure hydrocephalus. It is about diagnostic accuracy in practice and not about treating or curing the disease.
-
The complex molecular mechanism and pathophysiology of Alzheimer's disease (AD) limits the development of effective therapeutics or prevention strategies.
Why it matters
This review describes how artificial intelligence, combined with genetics and multi-omics data, is being used to search for Alzheimer's drugs, including repurposing existing drugs. It is a summary of methods and potential, not evidence that any treatment works.
-
47/100
Alzheimer disease (AD) is the most common form of dementia worldwide.
Why it matters
This review describes amyloid-related imaging abnormalities (ARIA), a complication of anti-amyloid antibody therapy for Alzheimer's disease, including how it is classified and monitored on MRI. It is about recognizing and managing a treatment side effect, not about curing or preventing the disease.
-
Brain cell-derived small extracellular vesicles (sEVs) in blood offer unique cellular and molecular information related to the onset and progression of Alzheimer's disease (AD).
-
The poor generalizability of clinical research data due to the enrollment of highly educated, non-Latinx White participants hampers the development of therapies for Alzheimer's disease (AD).
Why it matters
This perspective describes ways to include more Black and Latinx older adults in Alzheimer's cohort studies so results apply more broadly. It addresses research participation, not treating, curing, or preventing the disease.
-
Alzheimer's disease (AD) is the most common form of dementia worldwide, with a complex, poorly understood pathogenesis.
Why it matters
This review describes neuroinflammation as a prominent feature of the Alzheimer's brain and says substantial evidence suggests the inflammatory response modulates disease progression. It also notes that dysregulation of calcium homeostasis is another early factor in Alzheimer's pathogenesis, but no treatment or cure is reported.
-
Our data provide novel evidence that frontal lobe gamma activity is dampened in AD patients.
-
Alzheimer's disease (AD) is the most common form of dementia, affecting more than 50 million people worldwide with an estimated increase to 139 million people by 2050.
Why it matters
This review notes that the exact pathogenic mechanisms of Alzheimer's disease remain elusive and that current therapeutics focus on symptomatic management rather than preventative or curative strategies. It discusses the growing evidence for neuroinflammation but does not report any treatment, cure, or prevention for Alzheimer's disease.
-
Alzheimer's disease (AD), the most familiar type of dementia, is a severe concern in modern healthcare.
Why it matters
This review summarizes research on using deep learning for Alzheimer's disease diagnosis and notes that these techniques have been reported as more accurate than conventional machine learning models. It covers diagnosis only and states there is no proven cure, reporting no treatment or prevention.
-
Alzheimer's disease (AD) is the leading cause of cognitive impairment and dementia in older individuals (aged ≥ 65 years) throughout the world.
Why it matters
This review describes the humanistic and economic burden of Alzheimer's disease, including that mild cognitive impairment is associated with greater cost burden than normal cognition. It does not report on any treatment, cure, or prevention for Alzheimer's disease.
-
Growing evidence suggests a consistent association between atrial fibrillation (AF) and cognitive impairment and dementia that is independent of clinical stroke.
-
Previous research has shown that elevated blood C-reactive protein (CRP) is associated with increased Alzheimer disease (AD) risk only in APOE ε4 allele carriers; the objective of this study was to examine the interactive effects of plasma CRP and APOE genotype on cognition and AD biomarkers.
Why it matters
This study examined whether plasma C-reactive protein and APOE genotype interact to affect cognition and Alzheimer's disease biomarkers in 566 ADNI participants. It is an observational analysis of risk and markers, not a treatment, cure, or prevention for Alzheimer's disease.
-
47/100
Adults with Down syndrome (DS) have an exceptionally high prevalence of Alzheimer disease (AD), with an earlier age of onset compared with the neurotypical population.
Why it matters
In a retrospective study of 339 adults with Down syndrome, gout was associated with a delay of more than 2.5 years in the age at which Alzheimer's disease began. This is an observed association, not a demonstrated treatment or prevention, and the authors call for further studies.
-
This work validates the generalizability of MRI-based classification of Alzheimer's disease (AD) patients and controls (CN) to an external data set and to the task of prediction of conversion to AD in individuals with mild cognitive impairment (MCI).
Why it matters
MRI-based classification of Alzheimer's disease patients versus controls generalized to an external data set, with support vector machine and convolutional neural network performing similarly, and support vector machine performed significantly better than the neural network for predicting conversion in mild cognitive impairment. This is a diagnostic and prediction study and does not test treating, curing or preventing Alzheimer's disease.
-
Alzheimer's disease (AD) is an incurable neurodegenerative disease currently affecting 1.75% of the US population, with projected growth to 3.46% by 2050.
Why it matters
This study used a modified analysis pipeline to look at gene expression across multiple neocortical regions and implicated 8 genes across 6 genomic loci in Alzheimer's disease. It helps identify possible genetic targets for future research but does not test any treatment or cure.
-
Several studies, including genome wide association studies (GWAS), have strongly suggested a central role for the ATP-binding cassette transporter subfamily A member 7 (ABCA7) in Alzheimer's disease (AD).
Why it matters
This review describes evidence that the ABCA7 transporter is a genetic determinant for late-onset Alzheimer disease and regulates cholesterol metabolism and amyloid processing and clearance. It summarizes possible disease mechanisms but reports no treatment or prevention tested in patients.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Interleukin-1 mediates Alzheimer and Lewy body pathologies
- Maternal family history is associated with Alzheimer's disease biomarkers
- Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway
- Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2
- Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease
- Early diagnosis of Alzheimer's disease using machine learning: a multi-diagnostic, generalizable approach
- The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators
- Spines, plasticity, and cognition in Alzheimer's model mice
- White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study
- The Association Between Circulating Inflammatory Markers and the Progression of Alzheimer Disease in Norwegian Memory Clinic Patients With Mild Cognitive Impairment or Dementia